Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1874 1
1886 1
1887 1
1897 1
1901 1
1902 1
1908 1
1909 1
1911 1
1917 1
1920 1
1924 1
1928 1
1929 1
1930 1
1937 1
1943 1
1945 1
1946 2
1947 4
1948 2
1949 5
1950 9
1951 7
1952 3
1953 3
1954 5
1955 7
1956 8
1957 4
1958 9
1959 10
1960 7
1961 8
1962 2
1963 9
1964 8
1965 11
1966 12
1967 17
1968 18
1969 18
1970 29
1971 22
1972 18
1973 32
1974 19
1975 24
1976 34
1977 32
1978 23
1979 25
1980 35
1981 34
1982 37
1983 40
1984 41
1985 45
1986 54
1987 30
1988 55
1989 48
1990 57
1991 44
1992 57
1993 58
1994 59
1995 62
1996 70
1997 59
1998 43
1999 68
2000 71
2001 72
2002 80
2003 71
2004 87
2005 88
2006 96
2007 105
2008 131
2009 131
2010 118
2011 138
2012 145
2013 152
2014 170
2015 212
2016 229
2017 215
2018 149
2019 167
2020 183
2021 233
2022 179
2023 51
Text availability
Article attribute
Article type
Publication date

Search Results

4,368 results
Results by year
Filters applied: . Clear all
Page 1
FOXA1 overexpression suppresses interferon signaling and immune response in cancer.
He Y, Wang L, Wei T, Xiao YT, Sheng H, Su H, Hollern DP, Zhang X, Ma J, Wen S, Xie H, Yan Y, Pan Y, Hou X, Tang X, Suman VJ, Carter JM, Weinshilboum R, Wang L, Kalari KR, Weroha SJ, Bryce AH, Boughey JC, Dong H, Perou CM, Ye D, Goetz MP, Ren S, Huang H. He Y, et al. Among authors: carter jm. J Clin Invest. 2021 Jul 15;131(14):e147025. doi: 10.1172/JCI147025. J Clin Invest. 2021. PMID: 34101624 Free PMC article.
Digital Health Intervention in Acute Myocardial Infarction.
Marvel FA, Spaulding EM, Lee MA, Yang WE, Demo R, Ding J, Wang J, Xun H, Shah LM, Weng D, Carter J, Majmudar M, Elgin E, Sheidy J, McLin R, Flowers J, Vilarino V, Lumelsky DN, Bhardwaj V, Padula WV, Shan R, Huynh PP, Wongvibulsin S, Leung C, Allen JK, Martin SS. Marvel FA, et al. Among authors: carter j. Circ Cardiovasc Qual Outcomes. 2021 Jul;14(7):e007741. doi: 10.1161/CIRCOUTCOMES.121.007741. Epub 2021 Jul 15. Circ Cardiovasc Qual Outcomes. 2021. PMID: 34261332 Free PMC article. Clinical Trial.
Sequence- and structure-specific cytosine-5 mRNA methylation by NSUN6.
Selmi T, Hussain S, Dietmann S, Heiß M, Borland K, Flad S, Carter JM, Dennison R, Huang YL, Kellner S, Bornelöv S, Frye M. Selmi T, et al. Among authors: carter jm. Nucleic Acids Res. 2021 Jan 25;49(2):1006-1022. doi: 10.1093/nar/gkaa1193. Nucleic Acids Res. 2021. PMID: 33330931 Free PMC article.
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.
Carter JM, Polley MC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, Ma Y, Zahrieh D, Kachergus JM, Solanki M, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Thompson EA, Goetz MP. Carter JM, et al. Clin Cancer Res. 2021 Oct 15;27(20):5628-5637. doi: 10.1158/1078-0432.CCR-21-0343. Epub 2021 Jun 9. Clin Cancer Res. 2021. PMID: 34108182 Free PMC article.
Multi-modality machine learning predicting Parkinson's disease.
Makarious MB, Leonard HL, Vitale D, Iwaki H, Sargent L, Dadu A, Violich I, Hutchins E, Saffo D, Bandres-Ciga S, Kim JJ, Song Y, Maleknia M, Bookman M, Nojopranoto W, Campbell RH, Hashemi SH, Botia JA, Carter JF, Craig DW, Van Keuren-Jensen K, Morris HR, Hardy JA, Blauwendraat C, Singleton AB, Faghri F, Nalls MA. Makarious MB, et al. Among authors: carter jf. NPJ Parkinsons Dis. 2022 Apr 1;8(1):35. doi: 10.1038/s41531-022-00288-w. NPJ Parkinsons Dis. 2022. PMID: 35365675 Free PMC article.
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M; International Immuno-Oncology Biomarker Working Group. Gonzalez-Ericsson PI, et al. Among authors: carter jm. J Pathol. 2020 Apr;250(5):667-684. doi: 10.1002/path.5406. Epub 2020 Apr 9. J Pathol. 2020. PMID: 32129476 Free article. Review.
4,368 results